F. Hoffmann-La Roche Ltd: Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19

EMA's CHMP recommended the approval yesterdayApproval based on results from four phase III studies in over 5,500 patientsActemra/RoActemra has also been provisionally approved in Australia for the treatment

Related Keywords

Ghana ,Australia ,Japan ,United States ,Canada ,United Kingdom ,Australian ,America ,American ,Nathalie Meetz ,Levi Garraway ,Karl Mahler ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Sileia Urech ,Birgit Masjost ,Loren Kalm ,Actemra Roactemra ,Karsten Kleine ,Chugai Pharmaceutical Co Ltd ,Gilead Sciences Inc ,European Union ,Committee For Medicinal Products Human Use ,University Of Oxford ,University Of Oxford Randomised Evaluation ,Drug Administration ,World Health Organization ,European Commission ,Head Of Global Product Development ,Journal Of The American Medical Association ,Australian Therapeutic Goods Administration ,Approval Of Roche Products Pty Ltd ,European Medicines Agency ,Roche Group Media Relations ,Medicinal Products ,Human Use ,Chief Medical Officer ,Global Product ,Randomised Evaluation ,Evaluating Minority Patients ,Gilead Sciences ,American Medical Association ,Japan Actemra ,Emergency Use Authorization ,World Health Organization Model Lists ,Essential Medicines ,Dow Jones Sustainability ,Roactemra Summary ,Therapeutic Goods ,Provisional Approval ,Roche Products Pty Ltd ,Hoffmann ,Oche ,Roactemra ,Approved ,European ,Commission ,Treat ,Patients ,Evere ,Covid ,